Key Points
- Director Luke Evnin sold 80,459 shares of Werewolf Therapeutics on June 1 at an average price of $0.47, generating about $37,816. The sale was made under a pre-arranged Rule 10b5-1 trading plan.
- Evnin also made several additional share sales in late May and early June, with the latest reported trades totaling tens of thousands of shares each day. After the June 1 transaction, he still owned 542,120 shares, though his stake fell by 12.92%.
- Werewolf Therapeutics’ stock was trading near its 52-week low at $0.42, far below its $2.38 high, while analysts currently rate the stock a Hold on average with a $3.75 target price.
Werewolf Therapeutics, Inc. (NASDAQ:HOWL - Get Free Report) Director Luke Evnin sold 29,749 shares of the stock in a transaction dated Wednesday, June 3rd. The stock was sold at an average price of $0.42, for a total transaction of $12,494.58. Following the transaction, the director owned 482,776 shares of the company's stock, valued at approximately $202,765.92. This represents a 5.80% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Luke Evnin also recently made the following trade(s):
- On Tuesday, June 2nd, Luke Evnin sold 29,595 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.45, for a total transaction of $13,317.75.
- On Monday, June 1st, Luke Evnin sold 80,459 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.47, for a total transaction of $37,815.73.
- On Friday, May 29th, Luke Evnin sold 32,556 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.45, for a total transaction of $14,650.20.
- On Thursday, May 28th, Luke Evnin sold 27,698 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.46, for a total transaction of $12,741.08.
- On Wednesday, May 27th, Luke Evnin sold 80,852 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.48, for a total transaction of $38,808.96.
- On Tuesday, May 26th, Luke Evnin sold 67,950 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.47, for a total transaction of $31,936.50.
- On Friday, May 22nd, Luke Evnin sold 87,425 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.45, for a total transaction of $39,341.25.
- On Thursday, May 21st, Luke Evnin sold 36,387 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.42, for a total transaction of $15,282.54.
- On Wednesday, May 20th, Luke Evnin sold 85,895 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.43, for a total transaction of $36,934.85.
- On Tuesday, May 19th, Luke Evnin sold 62,970 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.45, for a total transaction of $28,336.50.
Werewolf Therapeutics Price Performance
NASDAQ:HOWL opened at $0.42 on Thursday. Werewolf Therapeutics, Inc. has a one year low of $0.40 and a one year high of $2.38. The company has a market cap of $20.53 million, a P/E ratio of -0.34 and a beta of 0.29. The firm's fifty day moving average price is $0.72 and its two-hundred day moving average price is $0.74.
Werewolf Therapeutics (NASDAQ:HOWL - Get Free Report) last released its quarterly earnings data on Thursday, May 7th. The company reported ($0.28) EPS for the quarter, beating the consensus estimate of ($0.32) by $0.04. As a group, equities research analysts expect that Werewolf Therapeutics, Inc. will post -1.29 earnings per share for the current year.
Institutional Investors Weigh In On Werewolf Therapeutics
Institutional investors have recently modified their holdings of the business. Vanguard Group Inc. boosted its position in shares of Werewolf Therapeutics by 8.5% in the third quarter. Vanguard Group Inc. now owns 1,408,047 shares of the company's stock valued at $2,774,000 after acquiring an additional 109,796 shares during the period. Bank of America Corp DE boosted its position in shares of Werewolf Therapeutics by 1.2% in the second quarter. Bank of America Corp DE now owns 2,129,024 shares of the company's stock valued at $2,321,000 after acquiring an additional 25,882 shares during the period. Renaissance Technologies LLC raised its position in shares of Werewolf Therapeutics by 48.6% in the fourth quarter. Renaissance Technologies LLC now owns 677,766 shares of the company's stock valued at $429,000 after buying an additional 221,766 shares in the last quarter. Jane Street Group LLC acquired a new stake in shares of Werewolf Therapeutics in the second quarter valued at approximately $409,000. Finally, Citadel Advisors LLC acquired a new stake in shares of Werewolf Therapeutics in the third quarter valued at approximately $304,000. Institutional investors own 64.84% of the company's stock.
Wall Street Analysts Forecast Growth
Several brokerages have issued reports on HOWL. Wall Street Zen downgraded shares of Werewolf Therapeutics from a "hold" rating to a "sell" rating in a research report on Saturday, May 9th. Weiss Ratings restated a "sell (d-)" rating on shares of Werewolf Therapeutics in a research note on Monday, April 20th. Two research analysts have rated the stock with a Buy rating, four have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, Werewolf Therapeutics currently has an average rating of "Hold" and an average target price of $3.75.
View Our Latest Stock Report on HOWL
Werewolf Therapeutics Company Profile
(
Get Free Report)
Werewolf Therapeutics, Inc (NASDAQ: HOWL) is a clinical-stage biotechnology company focused on the development of next-generation immunotherapies for the treatment of solid tumors. The company's proprietary Conditional Activation Platform is designed to keep therapeutic molecules inert in healthy tissues and selectively activate them within the tumor microenvironment, aiming to enhance anti-tumor efficacy while minimizing systemic toxicity.
Leveraging this platform, Werewolf Therapeutics is advancing multiple programs that include conditionally activated cytokine candidates and bi-specific antibody constructs.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
